ALVAL.PA实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (30 Apr 2024 @ 18:05):

Stats
今日成交量	12 346.00
平均成交量	30 020.00
市值	62.25M
EPS	€0 ( 2024-04-28 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-4.64
ATR14	€0.0130 (0.33%)

音量相关性

長: 0.16 (neutral)

短: 0.82 (strong)

Signal:(49.31) Same movement expected

Valbiotis SA 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Valbiotis SA 相关性 - 货币/商品

-0.14
( neutral )

-0.21
( neutral )

0.00
( neutral )

-0.15
( neutral )

0.61
( weak )

0.12
( neutral )

Valbiotis SA 财务报表

Annual	2023
营收:	€4.73M
毛利润:	€2.00M (42.26 %)
EPS:	€-0.590

FY	2023
营收:	€4.73M
毛利润:	€2.00M (42.26 %)
EPS:	€-0.590

FY	2022
营收:	€785 000
毛利润:	€767 000 (97.71 %)
EPS:	€-1.220

FY	2021
营收:	€2.05M
毛利润:	€1.63M (79.64 %)
EPS:	€-0.0828

Financial Reports:

No articles found.

Valbiotis SA

Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.